top of page

Free Biopharma Daily Stock Updates - 05/26/22

$XBI $68.47 | +1.09%

BiopharmIQ offers pro members full access to FDA Catalyst Calendar, PDUFA's, Biotech Stock Ideas.

Table of Contents:

Covid Updates

$MBRX +5.1% Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 source

$AXLA +16.8% Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio source

Pipeline Updates

$ACET +31.4% % Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL) source

$ADAP -1.4% Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track source

$IOVA -52.7% Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma source

$BBIO -0.2% bridgebio pharma presents positive phase 1 data in healthy volunteers, advancing development of bbp-671 for pantothenate kinase-associated neurodegeneration (pkan) and organic acidemias source

$SLS -8.8% SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer source

$CTMX +2.6% CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors source

$NRIX -22.7% Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development source

$RETA +3.4% Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia source


Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*


Business Updates



Posted by JM

bottom of page